Download PDF
Thromb Haemost 1990; 64(04): 506-510
DOI: 10.1055/s-0038-1647348
Original Article
Schattauer GmbH Stuttgart

Two Daily Subcutaneous Injections of Fragmin as Compared with Intravenous Standard Heparin in the Treatment of Deep Venous Thrombosis (DVT)

Göran Bratt
1   The Thrombosis Unit, the Department of Internal Medicine, Huddinge University Hospital, Stockholm, Sweden
,
Wiveca Åberg
1   The Thrombosis Unit, the Department of Internal Medicine, Huddinge University Hospital, Stockholm, Sweden
,
Margareta Johansson
1   The Thrombosis Unit, the Department of Internal Medicine, Huddinge University Hospital, Stockholm, Sweden
,
Eva Törnebohm
1   The Thrombosis Unit, the Department of Internal Medicine, Huddinge University Hospital, Stockholm, Sweden
,
Staffan Granqvist
2   The Department of Roentgenology, Huddinge University Hospital, Stockholm, Sweden
,
Dieter Lockner
1   The Thrombosis Unit, the Department of Internal Medicine, Huddinge University Hospital, Stockholm, Sweden
› Author Affiliations
Further Information

Publication History

Received 10 February 1989

Accepted after revision13 July 1990

Publication Date:
25 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

In a prospective, randomized, open study 119 consecutive patients with phlebographically verified deep venous thrombosis (DVT) of the leg (36% distal and 64% proximal) were treated either with a low molecular weight heparin (Fragmin, Kabi-Vitrum) subcutaneously (120 anti-FXa U/kg) twice daily or standard heparin (SH) as continuous intravenous infusion (480 IU kg−1 day−1). The Fragmin doses were adjusted to achieve an anti-FXa activity of 0.2-0.4 U/ml before injection and not greater than 1.5 U/ml 4 h after the morning injection. The SH dose was modified to prolong the APTT 2-3 times.

Repeat phlebography after 5-7 days showed improvement in 34/45 patients (76%) in the Fragmin group and in 30/49 patients (61%) in the SH group and progress in 2/45 (4%) and 3/49 (6%), respectively. The mean Marder scores decreased from 18.7 ± 12.1 to 15.7 ± 12.7 in the Fragmin group and from 16.9 ± 12.0 to 14.4 ± 11.8 in the SH group (ns). Two patients in the SH group and none in the Fragmin group had major bleedings.

After 22 ± 7 months follow up 6 rethromboses had occurred in the SH group and 4 in the Fragmin group. Postthrombotic signs and symptoms were similar in both groups.

We conclude that two daily sc Fragmin doses seem as effective and safe as continuous SH in the treatment of DVT of the leg.

 

  • References

  • 1 Borm JJ J, Kredit R, Sturk A, ten Cate JW. Heparin versus low molecular weight heparin K 2165 in chronic hemodialysis patients: a randomized cross-over study. Haemostasis 1986; (Suppl. 02) 16: 59-68
    PubMedSearch in Google Scholar
  • 2 Persson E. Lipoprotein lipase, hepatic lipase and plasma lipolytic activity. Effects of heparin and a low molecular weight heparin fragment (Fragmin). Thesis, Stockholm 1988: 724 Acta Med Scand
    PubMedSearch in Google Scholar
  • 3 Esquivel CO, Bergqvist D, Björk C-G, Nilsson B. Comparison between commercial heparin, low-molecular-weight heparin and pentosan polysulphate on hemostasis and platelets in vivo. Thromb Res 1982; 28: 389-399
    CrossrefPubMedSearch in Google Scholar
  • 4 Bratt G, Tömebohm E, Widlund L, Lockner D. Low molecular weight heparin (Kabi 2164, Fragmin): Pharmacokinetics after intravenous and subcutanous administration in human volunteers. Thromb Res 1986; 42: 613-620
    CrossrefPubMedSearch in Google Scholar
  • 5 Bergqvist D, Hedner U, Sjörin E, Holmer E. Anticoagulant effect of two types of low molecular weight heparin administered subcutan-ously. Thromb Res 1983; 32: 381-391
    CrossrefPubMedSearch in Google Scholar
  • 6 Bratt G, Tömebohm E, Lockner D, Bergström K. A human pharmacological study comparing heparin and low molecular weight heparin fragment. Thromb Haemostas 1985; 53: 208-211
    PubMedSearch in Google Scholar
  • 7 Bergqvist D, Mätzsch T, Burmark US, Frisell J, Guilbaud O, Hallböök T, Horn A, Lindhagen A, Ljungner H, Ljungström K-G, Onarheim H, Risberg B, Törngren S, Örtenwall P. Low molecular weight heparin given the evening before surgery compared with conventional low-dose heparin in prevention of thrombosis. Br J Surg 1988; 75: 888-891
    CrossrefPubMedSearch in Google Scholar
  • 8 Caen J. A randomized double-blind study between a low molecular weight heparin Kabi 2165 and Standard Heparin in the prevention of deep vein thrombosis in general surgery. Thromb Haemostas 1988; 59: 216-220
    PubMedSearch in Google Scholar
  • 9 Eriksson BI, Zachrisson BE, Teger-Nilsson AC, Risberg B. Thrombosis prophylaxis with low molecular weight heparin in total hip replacement. Br J Surg 1988; 75: 1053-1057
    CrossrefPubMedSearch in Google Scholar
  • 10 Schrader J, Stibbe W, Armstrong VW, Kandt M, Muche R, Kostering H, Seidel D, Scheler F. Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration. Kidney International 1988; 33: 890-896
    CrossrefPubMedSearch in Google Scholar
  • 11 Bratt G, Tomebohm E, Granqvist S, Aberg W, Lockner D. A comparison between low molecular weight heparin (Kabi 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. Thromb Haemostas 1985; 54: 813-817
    PubMedSearch in Google Scholar
  • 12 Albada H. et al. Comparison of Fragmin with Standard Heparin in the treatment of venous thromboembolism. In: Fragmin - The New Generation Antithrombotic Agent The Medicine Group (UK) Ltd; Oxford: 1987: 20-21
  • 13 Rabinov K, Paulin S. Röntgen diagnosis of venous thrombosis in the leg. Arch Surg 1972; 104: 134-144
    CrossrefPubMedSearch in Google Scholar
  • 14 Marder VJ, Soulen RL, Atichartakarn V, Budzynski AZ, Parulekar S, Kim JR, Edvard N, Zahavi J, Algazy KM. Quantitative venographic assessment of deep venous thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med 1977; 89: 1018-1029
    PubMedSearch in Google Scholar
  • 15 Holmer E, Söderberg K, Friberger P, Sörskog L. A new, simple chromogenic substrate assay for heparin and heparin-like activity in plasma. Thromb Haemostas 1985; 54: 29
    PubMedSearch in Google Scholar
  • 16 Andersson G, Fagrell B, Holmgren K, Johnsson H, Ljungberg B, Nilsson E, Wilhelsson S, Zetterquist S. Subcutaneous administration of heparin. A randomised comparison with intravenous administration of heparin to patients with deep-vein thrombosis. Thromb Res 1982; 27: 631-639
    CrossrefPubMedSearch in Google Scholar
  • 17 Bentley PG, Kakkar VV, Scully MF, MacGregor IR, Webb P, Chan P, Jones N. An objective study of alternative methods of heparin administration. Thromb Res 1980; 18: 177-187
    CrossrefPubMedSearch in Google Scholar
  • 18 Walker MG, Shaw JW, Thomson GJ L, Cumming JG R, Thomas ML. Subcutanous calcium heparin versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective randomised trial. Br Med J 1987; 294: 1189-1192
    CrossrefPubMedSearch in Google Scholar
  • 19 Doyle DJ, Turpie AG G, Hirsh J, Best C, Kinch D, Levine MN, Gent M. Adjusted subcutanous heparin or continous intravenous heparin in patients with acute deep vein thrombosis. Ann Intern Med 1987; 107: 441-445
    CrossrefPubMedSearch in Google Scholar
  • 20 Hull RD, Raskob GE, Hirsh J, Jay RM, Leclerc JR, Geerts WH, Rosenblom D, Sacket DL, Anderson C, Harrison L, Gent M. Continous intravenous heparin compared with intermittent subcutanous heparin in the initial treatment of proximal-vein thrombosis. New Engl J Med 1986; 315: 1109-1114
    CrossrefPubMedSearch in Google Scholar
  • 21 Dukes GE, Sanders SW, Russo J, Swenson E, Bumakis TG, Saffle JR, Warden GD. Transaminase elevations in patients receiving bovine or porcine heparin. Ann Intern Med 1984; 100: 646-650
    CrossrefPubMedSearch in Google Scholar
  • 22 Holm HA, Ly B, Handeland GF, Abildgaard U, Arnesen KE, Gottschalk P, Hoeg V, Aandahl M, Haugen K, Laerum F, Scheel B, Sortland O, Vinje B. Subcutanous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Haemostasis 1986; 16 (Suppl. 02) 30-37
    PubMedSearch in Google Scholar
  • 23 Marciniak E, Gockerman JP. Heparin-induced decrease in circulating antithrombin-III. Lancet 1977; II: 581-584
    PubMedSearch in Google Scholar
  • 24 Andersson G, Fagrell B, Holmgren K, Johnsson H, Ljungberg B, Wilhelmsson S. Antithrombin III in patients with acute deep vein thrombosis during heparin treatment (subcutanous and intravenous) and during and after treatment with oral coumarins. Thromb Res 1984; 34: 333-340
    CrossrefPubMedSearch in Google Scholar